Table 2.
Demographic, clinical, serological and therapeutic features in patients with palindromic rheumatism according to Anti-CarP status.
|
Anti-CarP positive
n = 13 |
Anti-CarP negative
n = 41 |
p value | |
|---|---|---|---|
| Female, n (%) | 7 (54%) | 27 (66%) | NS |
| Age, mean years (±SD) | 50.0 (±9.3) | 52.2 (±11.9) | NS |
| PR onset age, mean years (±SD) | 40.9 (±8.9) | 39.5 (±11.7) | NS |
| Disease duration since PR symptom onset, mean years (±SD) | 9.0 (±6.9.4) | 12.8 (±11.2) | NS |
| Ever smokers, n (%) | 8 (62%) | 26 (63%) | NS |
| Current smokers, n (%) | 6 (46%) | 11 (27%) | NS |
| Smoking cumulative dose ±SD | 15.8 ± 7.8 | 19.0 ± 17.9 | NS |
| Positive rheumatoid factor, n (%) | 10 (77%) | 21 (5%) | NS |
| Rheumatoid factor, mean titer (95% CI) | 239 (76–443) | 51 (34–74) | 0.012 |
| Positive ACPA, n (%) | 12 (92%) | 24 (59%) | 0.04 |
| ACPA, mean titer (95% CI) | 781 (418–1183) | 219 (124–339) | <0.005 |
| Frequency (periodicity) of PR flares | |||
| 1 month | 3 (23%) | 3 (7%) | NS |
| ⩾1 week | 3 (23%) | 8 (20%) | NS |
| PR flares duration | |||
| ⩽72 h, n (%) | 12 (92%) | 35 (85%) | NS |
| 72 h ⩽168 h, n (%) | 1 (8%) | 6 (15%) | NS |
| DMARDs | |||
| HCQ, n (%) | 5 (39%) | 15 (37%) | NS |
| MTX, n (%) | 1 (8%) | 5 (12%) | NS |
| DMARDs, not including HCQ, n (%) | 4 (31%) | 9 (22%) | NS |
| GC, n (%) | 2 (15%) | 6 (15%) | NS |
ACPA, anti-citrullinated protein/peptide autoantibodies; Anti-CarP, anti-carbamylated protein/peptide antibodies; CI, confidence interval; DMARD, disease-modifying anti-rheumatic drug; GC, glucocorticoid; HCQ, hydroxychloroquine; h, hours; MTX, methotrexate; n, number; NS, not significant; PR, palindromic rheumatism; SD, standard deviation.